Literature DB >> 21160980

Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Yu-Jing Zhang1.   

Abstract

In the etiology of hepatocellular carcinoma (HCC), in addition to hepatitis B virus and hepatitis C virus infections, chemical carcinogens also play important roles. For example, aflatoxin B(1) (AFB(1)) epoxide reacts with guanine in DNA and can lead to genetic changes. In HCC, the tumor suppressor gene p53 codon 249 mutation is associated with AFB(1) exposure and mutations in the K-ras oncogene are related to vinyl chloride exposure. Numerous genetic alterations accumulate during the process of hepatocarcinogenesis. Chemical carcinogen DNA-adduct formation is the basis for these genetic changes and also a molecular marker which reflects exposure level and biological effects. Metabolism of chemical carcinogens, including their activation and detoxification, also plays a key role in chemical hepatocarcinogenesis. Cytochrome p450 enzymes, N-acetyltransferases and glutathione S-transferases are involved in activating and detoxifying chemical carcinogens. These enzymes are polymorphic and genetic variation influences biological response to chemical carcinogens. This genetic variation has been postulated to influence the variability in risk for HCC observed both within and across populations. Ongoing studies seek to fully understand the mechanisms by which genetic variation in response to chemical carcinogens impacts on HCC risk.

Entities:  

Keywords:  4-aminobiphenyl; Aflatoxin B1; Chemical carcinogens; Cytochrome p450 enzymes; Genetic variation; Glutathione S-transferase; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Polycyclic aromatic hydrocarbons

Year:  2010        PMID: 21160980      PMCID: PMC2999273          DOI: 10.4254/wjh.v2.i3.94

Source DB:  PubMed          Journal:  World J Hepatol


  108 in total

1.  Roles of the vinyl chloride oxidation products 1-chlorooxirane and 2-chloroacetaldehyde in the in vitro formation of etheno adducts of nucleic acid bases [corrected].

Authors:  F P Guengerich
Journal:  Chem Res Toxicol       Date:  1992 Jan-Feb       Impact factor: 3.739

2.  Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens.

Authors:  T Shimada; C H Yun; H Yamazaki; J C Gautier; P H Beaune; F P Guengerich
Journal:  Mol Pharmacol       Date:  1992-05       Impact factor: 4.436

3.  Aflatoxin B1-2,3-oxide: evidence for its formation in rat liver in vivo and by human liver microsomes in vitro.

Authors:  D H Swenson; E C Miller; J A Miller
Journal:  Biochem Biophys Res Commun       Date:  1974-10-08       Impact factor: 3.575

4.  Sequential morphologic changes in aflatoxin B carcinogenesis in the rat.

Authors:  P M Newberne; G N Wogan
Journal:  Cancer Res       Date:  1968-04       Impact factor: 12.701

5.  Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1-and 4-aminobiphenyl-DNA adducts.

Authors:  Y J Zhang; S Chen; W Y Tsai; H Ahsan; R M Lunn; L Wang; C J Chen; R M Santella
Journal:  Biomarkers       Date:  2000       Impact factor: 2.658

6.  Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls.

Authors:  Shu-Yuan Chen; Li-Yu Wang; Ruth M Lunn; Wei-Yann Tsai; Po-Huang Lee; Chue-Shue Lee; Habibul Ahsan; Yu-Jing Zhang; Chien-Jen Chen; Regina M Santella
Journal:  Int J Cancer       Date:  2002-05-01       Impact factor: 7.396

7.  Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma.

Authors:  Masahiro Munaka; Kiyotaka Kohshi; Toshihiro Kawamoto; Shin Takasawa; Naoki Nagata; Hideaki Itoh; Susumu Oda; Takahiko Katoh
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-21       Impact factor: 4.553

Review 8.  Aflatoxins as risk factors for hepatocellular carcinoma in humans.

Authors:  G N Wogan
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

9.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.

Authors:  Lihua Ming; Snorri S Thorgeirsson; Mitchell H Gail; Peixin Lu; Curtis C Harris; Nengjin Wang; Yongfu Shao; Zhiyuan Wu; Guoting Liu; Xiaohong Wang; Zongtang Sun
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

10.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.

Authors:  G S Qian; R K Ross; M C Yu; J M Yuan; Y T Gao; B E Henderson; G N Wogan; J D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994 Jan-Feb       Impact factor: 4.254

View more
  10 in total

Review 1.  The Evolution of Carcinogenesis.

Authors:  Jeffrey M Peters; Frank J Gonzalez
Journal:  Toxicol Sci       Date:  2018-10-01       Impact factor: 4.849

Review 2.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

3.  Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.

Authors:  Agnès Marchio; Marie Amougou Atsama; Aubin Béré; Narcisse-Patrice Komas; Dominique Noah Noah; Paul Jean Adrien Atangana; Serge-Magloire Camengo-Police; Richard Njouom; Claudine Bekondi; Pascal Pineau
Journal:  Clin Exp Med       Date:  2018-05-10       Impact factor: 3.984

4.  MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1.

Authors:  Haile Qiu; Gehong Zhang; Bin Song; Junmei Jia
Journal:  Exp Ther Med       Date:  2019-07-25       Impact factor: 2.751

Review 5.  Non‑infective occupational risk factors for hepatocellular carcinoma: A review (Review).

Authors:  Caterina Ledda; Carla Loreto; Christian Zammit; Andrea Marconi; Lucrezia Fago; Serena Matera; Valentina Costanzo; Giovanni Fuccio Sanzà; Stefano Palmucci; Margherita Ferrante; Chiara Costa; Concettina Fenga; Antonio Biondi; Cristoforo Pomara; Venerando Rapisarda
Journal:  Mol Med Rep       Date:  2016-12-14       Impact factor: 2.952

6.  microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA.

Authors:  Zhennan Yun; Fanqi Meng; Peiqiang Jiang; Meng Yue; Shiquan Li
Journal:  Cancer Manag Res       Date:  2019-06-25       Impact factor: 3.989

Review 7.  Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

Authors:  Diwakar Suresh; Akshatha N Srinivas; Divya P Kumar
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

8.  Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma.

Authors:  Abdel Raouf Abou El Azm; Mohamed Yousef; Raafat Salah; Wael Mayah; Salwa Tawfeek; Hussien Ghorabah; Nagwa Mansour
Journal:  Springerplus       Date:  2013-02-25

Review 9.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

Review 10.  Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.

Authors:  Aakash Desai; Sonia Sandhu; Jin-Ping Lai; Dalbir Singh Sandhu
Journal:  World J Hepatol       Date:  2019-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.